APUS$2.91+0.69%
Apimeds Pharmaceuticals US, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: NYSE
Mkt Cap:$4.49M
Float & O/S:
Inst Own:
DilutionScan read 17 of Apimeds Pharmaceuticals US, Inc.'s SEC filings and found 3 warrant series, 4 convertibles, 1 S-1 registration and 1 completed offering on file for APUS. The latest dilution event on file is an offering on Dec 8, 2025. Analysis updated Sep 24, 2026.
Signal8 Summary
APUS
Going-concern warning, default on debt
Snapshot
APUS is a clinical-stage drug developer with zero revenue that has effectively become a crypto-and-blockchain holding company after a 2025 merger.
What's Happening Right Now
- : Interim CFO Erick Frim resigned September 29, 2026, and Eric Sherb was appointed CFO effective October 1, 2026 on a $60,000 base salary.
- : Subsidiary MindWave signed two 12-month blockchain agreements (AQUAEChain and FlashChain) paid mostly in equity and tokens with undisclosed dollar value.
- : APUS completed a 1-for-10 reverse split effective July 24, 2026, cutting shares outstanding from about 15.1M to 1.5M.
- : APUS gained additional Apitox-related rights, including a 25% royalty on future U.S. commercialization proceeds, via an assignment from FreeT Inc.
- : APUS reported a $55.2M six-month net loss with only $278K cash, disclosed going-concern doubt, and faces default on a $10.9M convertible note plus $5M of unpaid matured notes; it must regain NYSE American compliance by October 15, 2026 or risk delisting.
- : Raised $10.00M in gross proceeds through a private placement (PIPE), and a $10.90M convertible note.
- : Issued warrants over 75K shares.
- : Issued warrants over 20K shares.
